MeSH term
Frequency | Condition_Probility | Adult | 16 | 0.0 |
Aged | 3 | 0.0 |
Alleles | 12 | 0.0 |
DNA/genetics | 3 | 0.0 |
Fragile X Syndrome/*genetics | 26 | 16.0 |
Gene Frequency | 3 | 0.0 |
Humans | 55 | 0.0 |
Male | 40 | 0.0 |
Research Support, Non-U.S. Gov't | 45 | 0.0 |
X Chromosome/genetics | 4 | 2.0 |
Blotting, Southern | 8 | 0.0 |
CpG Islands/genetics | 3 | 2.0 |
Fragile X Syndrome/diagnosis/*genetics | 4 | 30.0 |
Genetic Screening/*methods | 3 | 2.0 |
Molecular Sequence Data | 14 | 0.0 |
Mutation/*genetics | 3 | 0.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Trinucleotide Repeat Expansion/genetics | 2 | 5.0 |
Animals | 5 | 0.0 |
Female | 36 | 0.0 |
Fragile X Syndrome/genetics | 6 | 18.0 |
Ovarian Failure, Premature/*genetics | 3 | 20.0 |
*X Chromosome | 14 | 1.0 |
Adolescent | 13 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Child | 14 | 0.0 |
Child, Preschool | 9 | 0.0 |
English Abstract | 2 | 0.0 |
Mental Retardation/*genetics | 12 | 5.0 |
Mutation | 10 | 0.0 |
Pedigree | 18 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Chromosome Fragile Sites | 8 | 5.0 |
Chromosome Fragility/*genetics | 2 | 11.0 |
Genetic Markers | 7 | 0.0 |
Heterozygote | 6 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Comparative Study | 3 | 0.0 |
Muscular Atrophy, Spinal/genetics | 2 | 25.0 |
Myotonic Dystrophy/genetics | 2 | 14.0 |
Trinucleotide Repeats/*genetics | 3 | 3.0 |
DNA Mutational Analysis | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
Mothers | 3 | 3.0 |
Prevalence | 3 | 0.0 |
DNA Methylation | 3 | 0.0 |
Genetic Counseling | 2 | 1.0 |
*Nuclear Proteins | 6 | 0.0 |
Phenotype | 5 | 0.0 |
Proteins/*genetics | 5 | 0.0 |
*Trans-Activators | 6 | 0.0 |
Base Sequence | 13 | 0.0 |
Chromosome Mapping | 9 | 0.0 |
*DNA Methylation | 2 | 0.0 |
*RNA-Binding Proteins | 10 | 3.0 |
Reference Values | 2 | 0.0 |
Restriction Mapping | 7 | 0.0 |
*Trinucleotide Repeats | 8 | 7.0 |
Brazil | 3 | 1.0 |
Genetic Screening | 3 | 0.0 |
Nerve Tissue Proteins/genetics | 4 | 1.0 |
Trinucleotide Repeats | 2 | 1.0 |
Amino Acid Sequence | 3 | 0.0 |
Linkage (Genetics) | 7 | 0.0 |
X Chromosome/*genetics | 4 | 1.0 |
Infant, Newborn | 3 | 0.0 |
Mental Retardation/genetics | 3 | 2.0 |
Sex Factors | 2 | 0.0 |
DNA/*genetics | 3 | 0.0 |
*Mutation | 2 | 0.0 |
*Chromosome Fragility | 8 | 6.0 |
Genotype | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Minisatellite Repeats | 2 | 1.0 |
Models, Genetic | 2 | 0.0 |
Nerve Tissue Proteins/*genetics | 4 | 0.0 |
Chromosome Fragility | 3 | 5.0 |
Infant | 2 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Cell Line | 3 | 0.0 |
Myotonic Dystrophy/*genetics | 2 | 3.0 |
Middle Aged | 4 | 0.0 |
Brain/metabolism | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Dinucleoside Phosphates | 2 | 11.0 |
Pregnancy | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 6 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
DNA Probes | 3 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
X Chromosome | 4 | 0.0 |
Heterozygote Detection | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Mice | 3 | 0.0 |
*Chromosomes, Human | 2 | 3.0 |
Genetic Diseases, Inborn/*genetics | 2 | 3.0 |
Methylation | 3 | 0.0 |
Hamsters | 2 | 0.0 |
X Chromosome/*ultrastructure | 2 | 8.0 |
*Chromosome Deletion | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Chromosome Banding | 4 | 0.0 |
Sex Chromosome Aberrations/*genetics | 3 | 4.0 |
*Sex Chromosome Aberrations | 2 | 6.0 |
